NEW Dividend Portfolio Tracker (DRIPTracker) is Now Live!
Track your stocks, dividends, monitor DRIP shares, and project your passive income.
Start Free »

PEN | NYSE

$319.67 $0.00 | 0.00%

Next Earnings: Sep 14, 2026

Company Overview:

Market Cap: $0
Trailing PE: 0x
FWD PE *: 57.7x
Payout Ratio (TTM):
52-Week Range: $221.26 - $362.41

* Forward PE is based on street estimates.

7.6 Year PEN Performance Metrics:

Total Return (with DRIP): 119.7% (10.91% CAGR)
Total Return (no DRIP): 119.7% (10.91% CAGR)
Share Price: 119.7% (10.91% CAGR)
Yield on Cost (with DRIP):
Total Invested: $10,000
Total Value (with DRIP): $21,969
Total Return $ (with DRIP): $11,969
PEN Total Return
1Y 2Y 5Y 10Y All
PEN Price Chart
1Y 2Y 5Y 10Y All
DRIPCalc.com
PEN Price

Unlock All Reports & Research Dividend Stocks.

Save 25% with annual plan (3 Months Free)
Pro
$171/yr ($14.25/mo)
7-day free trial
  • Unlimited Portfolio Tracker
  • Portfolio - Lots/Sales/Dividends
  • Portfolio Auto-DRIP
  • Stock Fundamentals
  • DCF valuation modeling
  • Compare Stocks Side-by-Side
  • Revenue & EPS Estimates
Start Free Trial
You save $57/yr (25%)
Most Popular
Premium
$288/yr ($24/mo)
7-day free trial
  • Everything in Pro
  • YieldMax PNL Tracker
  • YieldMax NAV Erosion Alerts
  • Stocks Dashboard
Start Free Trial
You save $96/yr (25%)
Ultra
$576/yr ($48/mo)
7-day free trial
  • Everything in Premium
  • Group & weekly ETF estimates
  • YouTuber Mode
  • Trades summary + CSV export
  • Priority data & support
Start Free Trial
You save $192/yr (25%)

PEN Earnings, Revenue, Cash & Debt, Shares Outstanding:

PEN - Revenue
PEN Revenue CAGR:1Y: 14.90%2Y: 14.14%5Y: 16.18%10Y: 19.61%
PEN - Earnings Per Share (EPS)
PEN EPS CAGR:1Y: -23.48%2Y: 0.00%5Y: 28.62%10Y: 65.82%
PEN - Net Income
🔒 Unlock
PEN Net Income CAGR:1Y: -23.10%2Y: 0.00%5Y: 30.40%10Y: 68.83%
PEN - EBITDA
🔒 Unlock
PEN EBITDA CAGR:1Y: 1.91%2Y: 0.00%5Y: 30.32%10Y: 0.00%
PEN - Free Cash Flow
🔒 Unlock
PEN Free Cash Flow CAGR:1Y: 10.81%2Y: 34.18%5Y: 0.00%10Y: 0.00%
PEN - Free Cash Flow / Share
🔒 Unlock
PEN Free Cash Flow / Share CAGR:1Y: 9.46%2Y: 33.29%5Y: 0.00%10Y: 0.00%
PEN - Operating Income
🔒 Unlock
PEN Operating Income CAGR:1Y: 0.52%2Y: 0.00%5Y: 31.82%10Y: 0.00%
PEN - Gross Profit
🔒 Unlock
PEN Gross Profit CAGR:1Y: 18.27%2Y: 28.54%5Y: 17.42%10Y: 20.38%
PEN - Shares Outstanding
🔒 Unlock
PEN Shares Outstanding CAGR:1Y: 0.83%2Y: 1.00%5Y: 1.04%10Y: 1.74%
PEN - Share Buybacks
🔒 Unlock
PEN Share Buybacks CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
PEN - Stock-Based Comp
🔒 Unlock
PEN Stock-Based Comp CAGR:1Y: -4.04%2Y: 19.53%5Y: 6.86%10Y: 14.52%
PEN - Expenses
🔒 Unlock
PEN Expenses CAGR:1Y: -13.08%2Y: 72.78%5Y: 32.67%10Y: 18.03%
PEN - Revenue vs Net Income
🔒 Unlock
PEN - EPS vs FCF / Share
🔒 Unlock
PEN - EPS vs PE Ratio
🔒 Unlock
PEN - FCF vs FCF / Share
🔒 Unlock
PEN - FCF vs Stock Based Comp
🔒 Unlock
PEN - Cash & Debt
🔒 Unlock
PEN - Revenue by Segment
🔒 Unlock
PEN Revenue CAGR:1Y: 14.90%2Y: 14.14%5Y: 16.18%10Y: 19.61%
PEN - Revenue by Region
🔒 Unlock
PEN Revenue CAGR:1Y: 14.90%2Y: 14.14%5Y: 16.18%10Y: 19.61%

Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:

PEN - REVENUE: Actual + Estimates
🔒 Unlock
PEN Actual Revenue CAGR:1Y: 14.90%2Y: 14.14%5Y: 16.18%10Y: 19.61%
PEN - EPS: Actual + Estimates
🔒 Unlock
PEN Actual EPS CAGR:1Y: -23.48%2Y: 0.00%5Y: 28.62%10Y: 65.82%
PEN - NET INCOME: Actual + Estimates
🔒 Unlock
PEN Actual Net Income CAGR:1Y: -23.10%2Y: 0.00%5Y: 30.40%10Y: 68.83%
PEN - EBITDA: Actual + Estimates
🔒 Unlock
PEN Actual EBITDA CAGR:1Y: 1.91%2Y: 0.00%5Y: 30.32%10Y: 0.00%

Ratios, Profit Margins & Return on Capital:

PEN - Net Profit Margin
🔒 Unlock
PEN Net Profit Margin CAGR:1Y: -33.13%2Y: 0.00%5Y: 12.23%10Y: 41.36%
PEN - Gross Profit Margin
🔒 Unlock
PEN Gross Profit Margin CAGR:1Y: 2.94%2Y: 12.63%5Y: 1.07%10Y: 0.65%
PEN - Price to Earnings
🔒 Unlock
PEN - Price To Sales Ratio
🔒 Unlock
PEN - Return on Capital Employed
🔒 Unlock
PEN - Return on Invested Capital
🔒 Unlock

Compare stocks side-by-side
 

Projected Future Returns & Dividends for PEN

Based on past 7.6-year performance, here are PEN growth metrics:

Share price CAGR of +10.91%
Dividend CAGR of +0%

Using PEN CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, is modelled to grow as follows:

PEN (DRIP)PEN - No DRIP
Current Price$319.67$319.67
Start Shares31.2831.28
Start Value$10,000$10,000
  
After 10 years:
Final Share Count31.2831.28
Dividends Payment$0.00$0.00
Annual Dividends$0$0
Yield on cost0.00%0.00%
Share Price$319.67$319.67
Total Dividends$0$0
Final Value$10,000$10,000

Estimated Future Value + Dividends - PEN

NOTE: Above numbers are our estimate based on PEN's Dividend and Price CAGR over past 7.6 years. These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.

We cannot guarantee that your actual returns will meet these estimates.

Get the best Dividend Stock Research Tools:

Save 25% with annual plan (3 Months Free)
Pro
$171/yr ($14.25/mo)
7-day free trial
  • Unlimited Portfolio Tracker
  • Portfolio - Lots/Sales/Dividends
  • Portfolio Auto-DRIP
  • Stock Fundamentals
  • DCF valuation modeling
  • Compare Stocks Side-by-Side
  • Revenue & EPS Estimates
Start Free Trial
You save $57/yr (25%)
Most Popular
Premium
$288/yr ($24/mo)
7-day free trial
  • Everything in Pro
  • YieldMax PNL Tracker
  • YieldMax NAV Erosion Alerts
  • Stocks Dashboard
Start Free Trial
You save $96/yr (25%)
Ultra
$576/yr ($48/mo)
7-day free trial
  • Everything in Premium
  • Group & weekly ETF estimates
  • YouTuber Mode
  • Trades summary + CSV export
  • Priority data & support
Start Free Trial
You save $192/yr (25%)

Company Info

Penumbra, Inc. (PEN) had its IPO on 2015-09-18, and is trader on NYSE stock exchange.

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.

PEN website: https://www.penumbrainc.com


Get Full Access to All Reports with DRIPCalc PRO

Save 25% with annual plan (3 Months Free)
Pro
$171/yr ($14.25/mo)
7-day free trial
  • Unlimited Portfolio Tracker
  • Portfolio - Lots/Sales/Dividends
  • Portfolio Auto-DRIP
  • Stock Fundamentals
  • DCF valuation modeling
  • Compare Stocks Side-by-Side
  • Revenue & EPS Estimates
Start Free Trial
You save $57/yr (25%)
Most Popular
Premium
$288/yr ($24/mo)
7-day free trial
  • Everything in Pro
  • YieldMax PNL Tracker
  • YieldMax NAV Erosion Alerts
  • Stocks Dashboard
Start Free Trial
You save $96/yr (25%)
Ultra
$576/yr ($48/mo)
7-day free trial
  • Everything in Premium
  • Group & weekly ETF estimates
  • YouTuber Mode
  • Trades summary + CSV export
  • Priority data & support
Start Free Trial
You save $192/yr (25%)